

Synthesis of fluorescent *O*-Coumarin glycosides as Potential drug delivery systems for MAO inhibitors

Antonio Franconetti,* Óscar López, Pastora Borrachero, José G. Fernández-Bolaños and Francisca Cabrera-Escribano

Departamento de Química Orgánica, Facultad de Química, Universidad de Sevilla, C/ Profesor García González, 1 41012 Seville, Spain; Tel: +34954556868.

**E-mail: afanconetti@us.es*

Abstract

MAO inhibitors have increased their importance as a result of the high incidence of neurodegenerative diseases such as Parkinson or Alzheimer. Herein, we report the synthesis and characterization of coumarin glycosides by reaction of a glycosyl halide with coumarin derivatives as well as mechanistic considerations based on DFT calculations. Additionally, the determination of the enzymatic parameters has shown that the carbohydrate-coumarin derivative is an efficient drug-releasing system.

Keyword

Coumarins, carbohydrates, MAO inhibitors, neurodegenerative diseases

Introduction

Nowadays, the high prevalence and incidence¹ of neurodegenerative diseases, such as Parkinson, Alzheimer or amyotrophic lateral sclerosis diseases makes an important field to search for novel molecules to access different customized treatment. In this context, monoaminoxidase (MAO) inhibitors have been used for this purpose in the initial stage of Parkinson's disease.²

In nature, two isoenzymes of MAO (MAO A and B) are described and located in the most of mammalian tissues.^{3,4} However, both enzymes present different tissue distribution, physiological function and substrate specificity. These isoforms act on a variety of endogenous and exogenous amine derivatives as neurotransmitters.⁵ For this reason, their inhibitions can involve an enhancement of neurotransmitters (*i.e.* dopamine) in cellular medium.

Coumarins have demonstrated to provide a wide range of biological activities including MAO inhibitor capability.⁶ Additionally, this kind of compounds shows fluorescent properties that improving its detection at physiological environments. However, these

compounds often suffer from poor solubility. With the aim of solving this drawback, following the strategy carrier pro-drug, coumarin attachment to a carbohydrate residue allowed us to improve this disadvantage.

In this communication we report the synthesis of coumarinyl glycosides by reaction of a glycosyl halide with coumarin derivatives and their characterization. The reaction has been optimized to achieve good selectivities and yields. For this purpose, mechanistic considerations based on DFT calculations have been also performed. In addition, the determination of the enzymatic parameters has shown that the carbohydrate-coumarin derivative is an efficient drug-releasing system.

Experimental Methods

All chemicals were purchased and used without further purification. Evaporations were conducted under reduced pressure. TLC was performed on silica gel plates (DC-Alufolien F₂₅₄, E. Merck). All new compounds were synthesized following the general procedure. Detection of compounds was accomplished with UV light (254 nm) and by charring with H₂SO₄ and characterization by ¹H and ¹³C NMR spectroscopy and Mass spectrometry.


General Procedure for glycosylation reactions

To a solution of glycosyl bromide (1 equiv.) in MeCN (45 mL) was successively added coumarin derivative (1.2 equiv.) and H₂O (500 μL). Then, K₂CO₃ (1.2 equiv.) was added to the reaction mixture. The heterogeneous reaction mixture was stirred at 60 °C for 1h monitoring by TLC. The reaction was filtered off a celite pad and concentrated under reduced pressure. The residue was dissolved in DCM (40 mL) and washed with 2 M NaOH (3 × 40 mL). The organic layer was dried with Na₂SO₄ and concentrated. Recrystallization from MeOH gave the coumarinyl glycoside in acceptable yield.

Spectral data for compound **3**: ¹H RMN (300 MHz, CDCl₃, δ ppm): δ 7.65 (1H, d, *J*_{4',3'} 9.6 Hz, H-4'), 7.40 (1H, d, *J*_{5',6'} 8.5 Hz, H-5'), 6.96 (1H, d, *J*_{8',6'} 2.0 Hz, H-8'), 6.91 (1H, dd, *J*_{6',8'} 2.3, *J*_{6',5'} 8.5 Hz, H-6'), 6.32 (1H, d, *J*_{3',4'} 9.5 Hz, H-3'), 5.33-5.27 (2H, m, H-1 y H-3), 5.20-5.13 (2H, m, H-2 y H-4), 4.29 (1H, dd, *J*_{6,5} 5.7, *J*_{6,6''} 12.3 Hz, H-6), 4.19 (1H, dd, *J*_{6'',5} 2.1, *J*_{6'',6} 12.3 Hz, H-6''), 3.92 (1H, m, H-5), 2.11 (3H, s, OCOCH₃), 2.07 (6H, s, OCOCH₃), 2.04 (3H, s, OCOCH₃).

Results and discussion


Synthesis of coumarinyl glycosides (**3-6**) were prepared following the experimental procedure described above from acetobromo- α -D-glucose (**1**) used as acceptor (Scheme 1).



Scheme 1

Previously, an optimization of reaction conditions was performed in order to obtain the desired coumarinyl glycoside instead of elimination byproduct **11** which synthesis is mediated by unexpected dehydrohalogenation in the reaction medium. For this purpose, several modifications of base, solvent, additive and temperature were realized. Coupling constant measured ($J_{1,2} \sim 8.0$ Hz) in ^1H NMR spectrum exclusively shows the selective formation of β anomer.

Additionally, DFT calculations by using B3LYP 6-31G level of theory include in GAMESS package were also applied to understand electronic and steric factors which govern the glycosylation reaction. Results bring to light two intermediates (II and III, Scheme 2) for each reaction pathway, respectively. Taking into account the corresponding energies (G, kJ/mol) elimination byproduct was more stable than desired glycoside. This fact could clearly explain our experimental results.



Scheme 2

Finally, enzymatic molecular recognition was explored by using enzymatic and docking studies. With the aim to simulate *in vivo* delivery by endogenous enzyme, Michaelis-Menten constants (K_m) for deprotected glycosidases (**7-10**) were determined from Hanes-Woolf plots. For docking⁷ simulation a pre optimized structure for coumarinyl D-galactoside with B3LYP 6-31G (d,p) was used.

Conclusions

An efficient and easy route to access to carbohydrate-coumarin systems have been successfully carried out. Furthermore, DFT calculations prove to be essential to understand the unexpected dehydrobromination which impede an improvement on the glycosylation yield.

Docking and enzymatic assays have been performed to calculated the affinity of our system for β -glycosidases (*e.g.* K_m 3.25 mM for compound **7**) providing a novel drug delivery capability of these derivatives.

Acknowledgements

We thank the AECID (Projects A/023577/09 and A/030422/10) and the ‘Junta de Andalucía’ (FQM 142 and Project P09-AGR-4597) for financial support.

References

1. *Neurological disorders: public health challenges*. Ed.; World Health Organization, Switzerland, **2006**.
2. Youdim, M. B. Edmondson, D.; Tripton, K. F. *Nat. Rev. Neurosci.* **2006**, *7*, 295-309
3. Shih, J. C.; Chen, K.; Ridd, M. J. *Annu. Rev. Neurosci.* **1999**, *22*, 197-217.
4. Tripton, K. F.; Boyce, S.; O' Sullivan, J.; Davey, G. P. Healy, J. *Curr. Med. Chem.* **2004**, *11*, 1965-1982.
5. Wang, C. C.; Billet, E.; Borchet, A.; Kuhn, H.; Ufer, C. *Cell. Mol. Life Sci.* **2013**, *70*, 599-630.
6. Patil, P. O.; Bari, S. B.; Firke, S. D.; Deshmukh, P. K.; Donda, S. T.; Patil, D. A. *Bioorg. Med. Chem.* **2013**, *21*, 2434-2450.
7. Huang, S.-Y.; Zou, X. *Int. J. Mol. Sci.* **2010**, *11*, 3016-3034.